Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart cafraglutide, ...
Shares of Amgen (AMGN) are down $11.49, or 4%, to $282.51 in pre-market trading after the company reported data at 52 weeks in a Phase 2 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback